Roche Expands into Gene Therapy with Dyno Therapeutics Deal
Roche has partnered with Dyno Therapeutics to develop adeno-associated virus (AAV) vectors for gene therapies for nervous system diseases and liver-directed treatments, part of the Swiss drugmaker’s push to expand into gene therapies.
Under the deal, Roche will gain the use of Dyno’s artificial intelligence-based technology for identifying AAV capsids, protein shells that are a promising delivery vehicle for various gene therapies.
Full terms of the deal were not disclosed, but Dyno will receive an upfront payment followed by additional milestone payments as well as product royalties, with total payments possibly exceeding $1.8 billion, Roche said.
In May, Dyno struck deals with Novartis and Sarepta Therapeutics to license its CapsidMap platform for the development of gene therapies.